Treatment and Relapse Prevention of Typical and Atypical Optic Neuritis

Int J Mol Sci. 2022 Aug 29;23(17):9769. doi: 10.3390/ijms23179769.

Abstract

Optic neuritis (ON) is an inflammatory condition involving the optic nerve. Several important typical and atypical ON variants are now recognized. Typical ON has a more favorable prognosis; it can be idiopathic or represent an early manifestation of demyelinating diseases, mostly multiple sclerosis (MS). The atypical spectrum includes entities such as antibody-driven ON associated with neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody disease (MOGAD), chronic/relapsing inflammatory optic neuropathy (CRION), and sarcoidosis-associated ON. Appropriate and timely diagnosis is essential to rapidly decide on the appropriate treatment, maximize visual recovery, and minimize recurrences. This review paper aims at presenting the currently available state-of-the-art treatment strategies for typical and atypical ON, both in the acute phase and in the long-term. Moreover, emerging therapeutic approaches and novel steps in the direction of achieving remyelination are discussed.

Keywords: MOG; MS prevention; NMO; atypical optic neuritis treatment; typical optic neuritis.

Publication types

  • Review

MeSH terms

  • Aquaporin 4
  • Autoantibodies
  • Humans
  • Myelin-Oligodendrocyte Glycoprotein
  • Neuromyelitis Optica*
  • Optic Neuritis* / diagnosis
  • Optic Neuritis* / prevention & control
  • Secondary Prevention

Substances

  • Aquaporin 4
  • Autoantibodies
  • Myelin-Oligodendrocyte Glycoprotein

Grants and funding

This research received no external funding.